EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Antipsychotic dopamine D2 affinity and negative symptoms in remitted first episode psychosis patients

Franciska de Beer, Ben Wijnen, Lotte Wouda, Sanne Koops, Shiral Gangadin, Wim Veling, Nico van Beveren, Lieuwe de Haan, Marieke J H Begemann, HAMLETT-OPHELIA consortium, Iris E C Sommer

Schizophrenia Research · 2024

DOI: 10.1016/j.schres.2024.09.030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Schizophrenia Research, 2024. Verfasst von Franciska de Beer und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of Groningen, University Medical Centre Groningen, Department of Biomedical Sciences, Groningen, the Netherlands. Electronic address: f.de…. Hauptthemen laut MEDLINE: Psychotic Disorders, Antipsychotic Agents, Receptors, Dopamine D2. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Negative symptoms can be an integral part of schizophrenia spectrum pathology and can be secondary to other psychotic symptoms or caused by antipsychotic medication. As antipsychotic drugs differ in their affinity to dopamine receptors and some antipsychotics have partial agonistic effects, antipsychotic drugs are expected to vary in their ability to cause negative symptoms. The association between negative symptoms and antipsychotic medication divided into partial agonists, or antagonists with high or low D2 affinity was assessed in 310 remitted first episode psychosis (FEP) patients. Severity of negative symptoms was assessed with the Comprehensive Assessment of Symptoms and History, and the Positive and Negative Syndrome Scale. Linear regression analyses were performed while controlling for differences in clinical and sociodemographic characteristics between the groups using inverse probability of treatment weighting. Patients using partial agonists (n = 78) showed fewer negative symptoms compared to those using high affinity antagonists (n = 84). Patients using partial agonists displayed less severe negative symptoms compared to those using low affinity antagonists (n = 148) at a trend level (p = 0.051). Negative symptom severity was higher in patients who had higher antipsychotic doses. In remitted FEP patients, we observed that the use of antipsychotic medication classified as partial agonists was associated with lower severity of negative symptoms, while the use of antagonists with high D2 affinity was associated with more severe negative symptoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Psychotic DisordersAntipsychotic AgentsReceptors, Dopamine D2HumansMaleFemaleAdultYoung AdultPsychiatric Status Rating ScalesSchizophreniaDopamine AgonistsAdolescentDopamine D2 Receptor Antagonists

Stichwörter der Autor:innen

Antipsychotic medicationDopamine D(2) affinityFirst episode psychosisNegative symptoms

Substanzen

Antipsychotic AgentsReceptors, Dopamine D2DRD2 protein, humanDopamine AgonistsDopamine D2 Receptor Antagonists

Autor:innen und Institutionen

  • University of Groningen, University Medical Centre Groningen, Department of Biomedical Sciences, Groningen, the Netherlands. Electronic address: f.de.beer@umcg.nl.
  • Centre of Economic Evaluations & Machine Learning, Trimbos Institute, Netherlands Institute of Mental Health and Addiction, Utrecht, the Netherlands.
  • University of Groningen, University Medical Centre Groningen, Department of Biomedical Sciences, Groningen, the Netherlands.
  • University of Groningen, University Medical Centre Groningen, Department of Biomedical Sciences, Groningen, the Netherlands; University of Groningen, University Medical Centre Groningen, Department of Psychiatry, Gronin…
  • University of Groningen, University Medical Centre Groningen, Department of Psychiatry, Groningen, the Netherlands.
  • Parnassia Group for Mental Health Care, The Hague, the Netherlands; Department of Neuroscience, Erasmus Medical Centre, Rotterdam, the Netherlands; Department of Psychiatry, Erasmus Medical Centre, Rotterdam, the Nether…

Förderung

  • ZonMw

Zitieren

APA

de Beer, F., Wijnen, B., Wouda, L., Koops, S., Gangadin, S., Veling, W., van Beveren, N., de Haan, L., Begemann, M. J. H., HAMLETT-OPHELIA consortium, & Sommer, I. E. C. (2024). Antipsychotic dopamine D2 affinity and negative symptoms in remitted first episode psychosis patients. Schizophrenia Research. https://doi.org/10.1016/j.schres.2024.09.030

Vancouver

de Beer F, Wijnen B, Wouda L, Koops S, Gangadin S, Veling W, et al. Antipsychotic dopamine D2 affinity and negative symptoms in remitted first episode psychosis patients. Schizophrenia Research. 2024. doi:10.1016/j.schres.2024.09.030

BibTeX
@article{deBeer2024,
  author = {de Beer, Franciska and Wijnen, Ben and Wouda, Lotte and Koops, Sanne and Gangadin, Shiral and Veling, Wim and van Beveren, Nico and de Haan, Lieuwe and Begemann, Marieke J H and HAMLETT-OPHELIA consortium, HAMLETT-OPHELIA consortium and Sommer, Iris E C},
  title = {Antipsychotic dopamine D2 affinity and negative symptoms in remitted first episode psychosis patients},
  journal = {Schizophrenia Research},
  year = {2024},
  doi = {10.1016/j.schres.2024.09.030}
}
Kostenlos starten →